Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | AHR | P35869 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443475 | 0.85 | KDM4E (0.73) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL585270 | 0.83 | KDM4E (1.00) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL29502916 | 0.83 | KDM4E (1.00) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2775680 | 0.83 | KDM4E (0.70) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL23461860 | 0.81 | KDM4E (0.69) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9083963 | 0.81 | KDM4E (0.69) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2775867 | 0.81 | KDM4E (0.69) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30168106 | 0.81 | KDM4E (0.68) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6857835 | 0.81 | KDM4E (0.68) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1006030 | 0.79 | MAPT (0.67) | KDM4EAHRSMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874668-A | Main protease regulator and application thereof | 北京昌平实验室 | 2025-04-25 | — | — | CN | disclosed |
| CN-114957248-B | Pyrrolo pyrimidine compound and preparation method, pharmaceutical composition and application thereof | 南开大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-114957248-A | Pyrrolopyrimidine compound, and preparation method, pharmaceutical composition and application thereof | 南开大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-110869372-B | Compound and organic light-emitting element using same | 株式会社LG化学 | 2022-05-27 | — | — | CN | disclosed |
| CN-107915722-B | Compound and organic light-emitting element comprising same | 株式会社LG化学 | 2021-04-20 | — | — | CN | disclosed |
| CN-110869372-A | Novel compound and organic light-emitting element using same | 株式会社LG化学 | 2020-03-06 | — | — | CN | disclosed |
| CN-106255695-B | Compound and organic light-emitting element comprising same | 东进世美肯株式会社 | 2019-12-31 | — | — | CN | disclosed |
| EP-3056498-B1 | DIAZADIBENZOFURANE AND DIAZADIBENZOTHIOPHENE DERIVATIVES AND THEIR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG SDI CO LTD (KR) | 2018-09-19 | — | — | EP | disclosed |
| CN-107915722-A | Novel compound and organic light-emitting element comprising same | 株式会社LG化学 | 2018-04-17 | — | — | CN | disclosed |
| US-20170012216-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
| WO-2006014647-A2 | CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF | ATHERSYS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050277658-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050239793-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050239794-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227992-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005037825-A2 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227992-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | KDM4E 1499/4885AHR 3300/4885SMN1; SMN2 3186/4885 |
| US-20050277658-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | KDM4E 1499/4885AHR 3300/4885SMN1; SMN2 3186/4885 |
| US-20050239794-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | KDM4E 1499/4885AHR 3300/4885SMN1; SMN2 3186/4885 |
| US-20170012216-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | KDM4E 3527/4885AHR 2531/4885SMN1; SMN2 4723/4885 |
| US-20050239793-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | KDM4E 1499/4885AHR 3300/4885SMN1; SMN2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.